The European Union won’t weaken merger rules during the COVID-19 pandemic even if companies announced that they are likely to go bust without a deal, a senior EU antitrust official said on Wednesday, November 18.
European Commission Director General for Competition Olivier Guersent said he expected more companies to use the “failing firm defence” to try to justify mergers during the crisis, reported Reuters. However, he said regulators didn’t see the need to relax the rules.
“Why should we? What’s the rationale for that? Which criteria should we relax?” Guersent told an American Chamber of Commerce EU online event.
“We will not get out of this crisis better if we weaken competition policy,” he said.
He also said the Commission planned to offer guidance soon to companies involved in large investments and in digital projects to allow them to cooperate with peers without running foul of EU antitrust rules against cartels or anti-competitive practices.
Guersent issued a so-called comfort letter to the pharmaceutical industry in April so drugmakers can coordinate to increase production and to improve the supply of urgently needed critical hospital medicines to treat COVID-19 patients.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI